| Element List | Current Quarter | Similar quarter for previous year | %Change | Previous Quarter | % Change |
|---|---|---|---|---|---|
| Sales/Revenue | 319.09 | 301.88 | 5.7 | 339.5 | -6.011 |
| Gross Profit (Loss) | 101.09 | 96.51 | 4.745 | 90.5 | 11.701 |
| Operational Profit (Loss) | 52.55 | 76.73 | -31.513 | 59.2 | -11.233 |
| Net Profit (Loss) Attributable to Shareholders of the Issuer | 56.24 | 73.93 | -23.928 | 54.08 | 3.994 |
| Total Comprehensive Income Attributable to Shareholders of the Issuer | 52.76 | 75.24 | -29.877 | 52.84 | -0.151 |
| All figures are in (Millions) Saudi Arabia, Riyals | |||||
| Element List | Current Period | Similar period for previous year | %Change |
|---|---|---|---|
| Total Shareholders Equity (after Deducting Minority Equity) | 2,025.92 | 1,980.5 | 2.293 |
| Profit (Loss) per Share | 0.35 | 0.46 | |
| All figures are in (Millions) Saudi Arabia, Riyals | |||
| Element List | Amount | Percentage of the capital (%) | |
|---|---|---|---|
| Profit (Losses) Resulting From The Change In Investment Propertie’s Fair Value | – | – | |
| All figures are in (Millions) Saudi Arabia, Riyals | |||
| Element List | Explanation |
|---|---|
| The reason of the increase (decrease) in the sales/ revenues during the current quarter compared to the same quarter of the last year is | The Company achieved a 5.7% growth in revenues during the first quarter of the current year, reaching 319.09 million Saudi Riyals, compared to 301.88 million Saudi Riyals for the same quarter of the previous year.
This increase was primarily driven by the revenue growth in the Pharmaceutical Products segment, which rose by 17.7% to reach 72.15 million Saudi Riyals (compared to 61.31 million Saudi Riyals in the corresponding period last year). This performance was bolstered by a rise in retail sales through the company’s subsidiary. In a related context, the Medical Services segment contributed to the overall revenue growth by recording a 2.6% increase. The segment’s revenues reached 246.94 million Saudi Riyals, representing an increase of 6.37 million Saudi Riyals compared to the 240.57 million Saudi Riyals reported in the same quarter of the previous year. |
| The reason of the increase (decrease) in the net profit during the current quarter compared to the same quarter of the last year is | During the first quarter of 2026, net profit recorded a year-on-year (YoY) decrease of 23.9%, reaching 56.24 million Saudi Riyals compared to 73.93 million Saudi Riyals in the same quarter of the previous year. This decline in net profit is primarily attributed to the following factors:
1) The total General and Administrative (G&A), Selling, and Marketing expenses rose by 41.5% to reach 36.88 million Saudi Riyals in the current quarter, compared to 26.07 million Saudi Riyals in the corresponding quarter of last year. This increase is mainly due to advertising costs related to the rebranding campaign for Al Hammadi Hospitals Group. 2) The Expected Credit Loss provision expense for the current quarter recorded 17.31 million Saudi Riyals, compared to a provision reversal of 0.33 million Saudi Riyals in the same quarter of the previous year. This surge in provision expense is a result of delayed payments from some major clients. |
| The reason of the increase (decrease) in the sales/ revenues during the current quarter compared to the previous one is | The company’s revenues for the first quarter of 2026 reached 319.09 million Saudi Riyals, representing a 6.0% decrease compared to the fourth quarter of 2025, which stood at 339.50 million Saudi Riyals. This decline is primarily attributed to seasonal factors, as the current quarter coincided with the Holy Month of Ramadan and Eid Al-Fitr. These occasions led to a temporary impact on operational levels and business volumes within the Medical and Pharmaceutical sectors. |
| The reason of the increase (decrease) in the net profit (loss) during the current quarter compared to the previous one is | The company reported a 4.0% growth in net profit, reaching 56.24 million Saudi Riyals for the first quarter of 2026, compared to 54.08 million Saudi Riyals in the fourth quarter of 2025. Additionally, the net profit margin improved to 17.6%, up from 15.9% in the previous quarter. This growth is primarily attributed to the following factors:
1) The gross margin increased to 31.7% (compared to 26.7% in the previous quarter), driven by enhanced cost management and operational efficiency in revenue-related expenses. 2) A significant 174.8% increase in the company’s share of net profits from associates, amounting to 14.55 million Saudi Riyals in the first quarter of 2026. |
| Statement of the type of external auditor’s report | Unmodified conclusion |
| Comment mentioned in the external auditor’s report, mentioned in any of the following paragraphs (other matter, conservation, notice, disclaimer of opinion, or adverse opinion) | None |
| Reclassification of Comparison Items | None |
| Additional Information | – |
